A Phase I Study of the Safety and Feasibility of Azacitidine After Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Stem Cell Transplantation.

Trial Profile

A Phase I Study of the Safety and Feasibility of Azacitidine After Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome After Allogeneic Stem Cell Transplantation.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Aug 2013 Planned number of patients changed from 20 to 21 as reported by ClinicalTrials.gov.
    • 01 Mar 2013 Planned end date changed from 1 Jun 2013 to 1 Oct 2015 as reported by ClinicalTrials.gov.
    • 19 Jul 2012 Planned end date changed from 1 Apr 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top